EUCTR2014-002241-22-DE进行中（未招募）1 期
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma.
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •For Dose Escalation: Subjects with any previously treated advanced (metastatic or refractory) solid tumor type and B-cell non-Hodgkin lymphoma except subjects who have primary central nervous system tumors or with central nervous system metastases as the only site of active disease )
- •For Cohort Expansion: Subjects must have a previously treated advanced solid tumor or B cell non-Hodgkin’s lymphoma to be eligible:
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •For certain subjects, willing and able to provide pre-treatment and on-treatment fresh tumor biopsy
- •Women of child-bearing potential and men must use an acceptable method of contraception during treatment and for 23 weeks after treatment for women and 31 weeks for men.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 220
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •Known central nervous system metastases or central nervous system as the only source of disease
- •Other concomitant malignancies (with some exceptions per protocol)
- •Active, known or suspected autoimmune disease
- •Uncontrolled or significant cardiovascular disease
- •History of hepatitis (B or C)
- •History of active or latent tuberculosis.
研究者
相似试验
进行中（未招募）
1 期
A study to learn about the safety and efficacy of CTX110(the study drug product) to treat certain types of blood cancerEUCTR2018-003916-38-DECRISPR Therapeutics AG95
进行中（未招募）
1 期
Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab Solid Tumors and B-cell Non-Hodgkins LymphomaEUCTR2014-002241-22-ESBristol-Myers Squibb International Corporation260
进行中（未招募）
1 期
A Phase I/2a study of BMS-986156 given alone and in combination with nivolumab in subjects with advanced solid tumors.Advanced Solid TumorsMedDRA version: 19.0Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2015-002505-11-ESBristol-Myers Squibb International Corporation300
进行中（未招募）
1 期
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid TumorsEUCTR2014-002605-38-ATBristol-Myers Squibb International Corporation2,000
进行中（未招募）
1 期
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumorseoplasms by siteMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10067946Term: Renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002605-38-GBBristol-Myers Squibb International Corporation2,000